BeiGene breaks ground on new manufacturing and clinical R&D center at former BMS campus in Hopewell

HT Mayor Courtney Peters-Manning, BeiGene's Michael Schoen and US Congresswoman Bonnie Watson-Coleman. Russ DeSantis Photography and Video, LLC

BeiGene, Ltd. a global biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, has announced the groundbreaking of its flagship U.S. manufacturing and clinical R&D center at the Princeton West Innovation Campus in Hopewell, N.J.

“Our planned flagship U.S. R&D and manufacturing center supports our commitment to fight for life for people living with cancer around the world, through state-of-the-art commercial-stage biologic pharmaceutical manufacturing, late-stage research and clinical development capabilities,” said John Oyler, Co-Founder, Chairman and CEO of BeiGene. “The Princeton- Hopewell area is an excellent location for BeiGene and the thriving life science community, with a deep talent pool as we continue to advance our pipeline of innovative cancer medicines and work to diversify our global supply chain.”

The initial phase of construction is expected to include approximately 400,000 square feet of dedicated commercial-stage biologic pharmaceutical manufacturing space, with capacity for up to 16,000 liters of biologics formula. BeiGene intends to recruit hundreds of new hires from the area’s attractive talent market to support its continued growth and its commitment to producing life-saving oncology medicines.

Mayor Courtney Peters-Maning and Governor Phil Murphy. Russ DeSantis Photography and Video, LLC


“BeiGene’s plans for hundreds of new jobs in New Jersey speak to our efforts to grow our state’s business-friendly environment and to our commitment to fostering innovation,” said Governor Phil Murphy. “We are proud to welcome BeiGene to the Princeton area and look forward to the company manufacturing innovative cancer medicines in its new state-of-the-art facility.”

In November 2021, BeiGene acquired the Hopewell property from Lincoln Equities Group and has retained DPR Construction as its construction management firm and IPS as its architectural and engineering firm. The property has more than one million square feet of developable real estate for future potential expansion.

Added Oyler: “At BeiGene, we are committed to not only delivering innovative and affordable medicines but also to upholding the highest standards of ethics and integrity, operational excellence, and environmental stewardship. This commitment applies to everything we do, including the development of BeiGene’s Hopewell project.”

”As a leader with a long history in New Jersey’s biotech industry, Hopewell Township welcomes BeiGene to our community,” said Hopewell Township Mayor Courtney Peters-Manning “We are pleased that BeiGene will bring their state-of-the-art technologies, manufacturing, and R&D center to Hopewell, whose products will help countless people all over the world. We look forward to continuing to work with BeiGene and are excited about what will be produced here in Hopewell.”

BeiGene currently has five offices in the U.S., in San Mateo and Emeryville, Calif., Cambridge, Mass., Ridgefield Park, N.J. and Fulton, Md. Globally, the company has more than 30 offices across five continents.

BeiGene Oncology BeiGene is committed to advancing best- and first-in-class clinical candidates internally or with like-minded partners to develop impactful and affordable medicines for patients across the globe. We have a growing R&D and medical affairs team of approximately 2,900 colleagues dedicated to advancing more than 100 clinical trials that have involved more than 14,500 subjects. Our expansive portfolio is directed predominantly by our internal colleagues supporting clinical trials in more than 45 countries and regions. Hematology-oncology and solid tumor targeted therapies and immuno-oncology are key focus areas for the Company, with both mono- and combination therapies prioritized in our research and development. BeiGene currently has three approved medicines discovered and developed in our own labs: BTK inhibitor BRUKINSA in the United States, China, the EU and U.K., Canada, Australia and additional international markets; and the non-FC-gamma receptor binding anti-PD-1 antibody tislelizumab as well as the PARP inhibitor pamiparib in China.

BeiGene also partners with innovative companies who share our goal of developing therapies to address global health needs. We commercialize a range of oncology medicines in China licensed from Amgen, Bristol Myers Squibb, EUSA Pharma and Bio-Thera. We also plan to address greater areas of unmet need globally through our other collaborations including with Mirati Therapeutics, Seagen, and Zymeworks.

In January 2021 BeiGene and Novartis announced a collaboration granting Novartis rights to co-develop, manufacture, and commercialize BeiGene’s anti-PD1 antibody tislelizumab in North America, Europe, and Japan. Building upon this productive collaboration, including a biologics license application (BLA) under FDA review, BeiGene and Novartis announced an option, collaboration and license agreement in December 2021 for BeiGene’s TIGIT inhibitor ociperlimab that is in Phase 3 development. Novartis and BeiGene also entered into a strategic commercial agreement through which BeiGene will promote five approved Novartis Oncology products across designated regions of China.

If you rely on MercerMe for your local news, please support us.

To keep the news coming, we rely on support from subscribers and advertising partners. Hyperlocal, independent, and digital — MercerMe has been providing Hopewell Valley its news since 2013. Subscribe today.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.